Skip to content
Screener
Medicinova logo

Medicinova

MNOV

MediciNova is a biopharmaceutical company focused on developing and commercializing novel therapeutics for serious diseases with high unmet medical needs.

Market cap
$72.36M-6.0%

Earnings

Next report

Date not yet announced

Competitors

Profile

MediciNova is a biopharmaceutical company focused on developing and commercializing novel therapeutics for serious diseases with high unmet medical needs. The company primarily targets neurological disorders, fibrotic conditions, and metabolic diseases, leveraging a strategy of acquiring early-stage compounds and advancing them through clinical development in the United States.

Competitive position

A clinical-stage developer utilizing a capital-efficient model by leveraging investigator-sponsored trials and government grants to advance a diverse pipeline of orphan-designated and fast-track candidates.

GeographiesUnited States, Canada, United Kingdom
Customer segmentsPharmaceutical companies, Healthcare providers, Patients
Business modelR&D focused, Licensing and Royalties, B2B
SuppliersContract Manufacturing Organizations (CMOs), Active Pharmaceutical Ingredient (API) suppliers, Academic research institutions, Licensors of intellectual property
CustomersLarge pharmaceutical companies, Strategic commercialization partners, Clinical trial networks
Listed2006
Employees13.0
CEOYuichi Iwaki
FilingsSEC EDGAR

FAQ

What is Medicinova's market cap?
Medicinova (MNOV) has a market capitalization of $72.4M and trades on NASDAQ.
Who are Medicinova's competitors?
Medicinova's key competitors include Ionis Pharmaceuticals, Madrigal Pharmaceuticals, Pfizer, and others. These companies compete in similar markets and product categories.
Who does Medicinova partner with?
Medicinova's notable partners include Kyorin Pharmaceutical Co., Ltd., National Institute of Neurological Diseases and Stroke, University of Cambridge, and others.
Where is Medicinova headquartered?
Medicinova is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2006.